220 related articles for article (PubMed ID: 24856188)
21. Lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma: genomic profiles, gene fusions, and clinical characteristics.
von Holstein SL; Fehr A; Persson M; Nickelsen M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
Ophthalmology; 2014 May; 121(5):1125-33. PubMed ID: 24468654
[TBL] [Abstract][Full Text] [Related]
22. t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma.
O'Neill ID
Oral Oncol; 2009 Jan; 45(1):2-9. PubMed ID: 18486532
[TBL] [Abstract][Full Text] [Related]
23. CRTC1-MAML2 and CRTC3-MAML2 fusions were not detected in metaplastic Warthin tumor and metaplastic pleomorphic adenoma of salivary glands.
Skálová A; Vanecek T; Simpson RH; Vazmitsel MA; Majewska H; Mukensnabl P; Hauer L; Andrle P; Hosticka L; Grossmann P; Michal M
Am J Surg Pathol; 2013 Nov; 37(11):1743-50. PubMed ID: 24121173
[TBL] [Abstract][Full Text] [Related]
24. New approaches in salivary gland carcinoma.
Even C; Baste N; Classe M
Curr Opin Oncol; 2019 May; 31(3):169-174. PubMed ID: 30844885
[TBL] [Abstract][Full Text] [Related]
25. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
Cavalieri S; Platini F; Bergamini C; Resteghini C; Galbiati D; Bossi P; Perrone F; Tamborini E; Quattrone P; Licitra L; Locati LD; Alfieri S
Expert Opin Investig Drugs; 2019 May; 28(5):435-443. PubMed ID: 30897975
[TBL] [Abstract][Full Text] [Related]
26. A molecular guide to systemic therapy in salivary gland carcinoma.
Weaver AN; Lakritz S; Mandair D; Ulanja MB; Bowles DW
Head Neck; 2023 May; 45(5):1315-1326. PubMed ID: 36859797
[TBL] [Abstract][Full Text] [Related]
27. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation.
Komiya T; Park Y; Modi S; Coxon AB; Oh H; Kaye FJ
Oncogene; 2006 Oct; 25(45):6128-32. PubMed ID: 16652146
[TBL] [Abstract][Full Text] [Related]
28. Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.
Di Villeneuve L; Souza IL; Tolentino FDS; Ferrarotto R; Schvartsman G
Front Oncol; 2020; 10():580141. PubMed ID: 33194707
[TBL] [Abstract][Full Text] [Related]
29. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene.
Behboudi A; Enlund F; Winnes M; Andrén Y; Nordkvist A; Leivo I; Flaberg E; Szekely L; Mäkitie A; Grenman R; Mark J; Stenman G
Genes Chromosomes Cancer; 2006 May; 45(5):470-81. PubMed ID: 16444749
[TBL] [Abstract][Full Text] [Related]
30. Oncocytic mucoepidermoid carcinoma of the parotid gland with CRTC1-MAML2 fusion transcript: report of a case with review of literature.
Fujimaki M; Fukumura Y; Saito T; Mitani K; Uchida S; Yokoyama J; Yao T; Ikeda K
Hum Pathol; 2011 Dec; 42(12):2052-5. PubMed ID: 21676434
[TBL] [Abstract][Full Text] [Related]
31. Histologic grading and prognostic biomarkers in salivary gland carcinomas.
Seethala RR
Adv Anat Pathol; 2011 Jan; 18(1):29-45. PubMed ID: 21169736
[TBL] [Abstract][Full Text] [Related]
32. Biology and management of salivary gland cancers.
Adelstein DJ; Koyfman SA; El-Naggar AK; Hanna EY
Semin Radiat Oncol; 2012 Jul; 22(3):245-53. PubMed ID: 22687949
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
34. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma.
Okabe M; Miyabe S; Nagatsuka H; Terada A; Hanai N; Yokoi M; Shimozato K; Eimoto T; Nakamura S; Nagai N; Hasegawa Y; Inagaki H
Clin Cancer Res; 2006 Jul; 12(13):3902-7. PubMed ID: 16818685
[TBL] [Abstract][Full Text] [Related]
35. Dynamic Role of miRNAs in Salivary Gland Carcinomas: From Biomarkers to Therapeutic Targets.
Kimura TC; de Lima-Souza RA; Maciel TF; Kowalski LP; Coutinho-Camillo CM; Egal ESA; Altemani A; Mariano FV
Head Neck Pathol; 2024 Feb; 18(1):12. PubMed ID: 38393615
[TBL] [Abstract][Full Text] [Related]
36. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.
Nakano T; Yamamoto H; Hashimoto K; Tamiya S; Shiratsuchi H; Nakashima T; Nishiyama K; Higaki Y; Komune S; Oda Y
Histopathology; 2013 Sep; 63(3):378-92. PubMed ID: 23855785
[TBL] [Abstract][Full Text] [Related]
37. Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).
Marchiò C; Weigelt B; Reis-Filho JS
J Clin Pathol; 2010 Mar; 63(3):220-8. PubMed ID: 20203221
[TBL] [Abstract][Full Text] [Related]
38. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
Schwarz S; Ettl T; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Oral Oncol; 2008 Jun; 44(6):563-70. PubMed ID: 17936671
[TBL] [Abstract][Full Text] [Related]
39. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
Locati LD; Perrone F; Losa M; Mela M; Casieri P; Orsenigo M; Cortelazzi B; Negri T; Tamborini E; Quattrone P; Bossi P; Rinaldi G; Bergamini C; Calderone RG; Liberatoscioli C; Licitra L
Oral Oncol; 2009 Nov; 45(11):986-90. PubMed ID: 19574086
[TBL] [Abstract][Full Text] [Related]
40. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
